LOS ANGELES, CA--(Marketwire - Mar 26, 2012) - Last week, shares of Pozen Inc. (NASDAQ: [ POZN ]) -- a developer of novel pharmacologic agents primarily for pain and pain-related conditions -- rose the most in four months after announcing positive top-line results from two pivotal Phase 3 clinical trials. Will shares continue higher based on fundamentals and more upcoming catalysts?

Last week, the Chapel Hill, North Carolina-based firm said the newly released information from the studies is essential to progress their drug candidate's ([ PA32540 ]) partnership discussions in the United States, and that it will continue to move forward with preparations for a third quarter NDA submission with the FDA.

John R. Plachetka, Pharm.D., the Company's Chairman, President and Chief Executive Officer, responded to some questions about the key news development.

His answers regarding the PA32540 Phase 3 results are now available in a special BioMedReport:
[ http://www.biomedreports.com/2012032691906/pozens-fundamentals-continue-to-improve.html ]

Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to:
[ http://biomedreports.com/fdacal.html ]

News developments and live healthcare sector updates are available constantly via Twitter at: [ http://twitter.com/BioMedReports ]

About BioMedReports.Com

BioMedReports is a news and research portal covering financial biomedical news and the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. They sell a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release is available at BioMedReports.Com.